Criteria for malignancy in gastrointestinal endocrine tumors

Endocrine Pathology

Volumn 17, Issue 2, 2006, Pages 119-129

  Bordi, Cesare ^a   D'Adda, Tiziana ^a   Azzoni, Cinzia ^a   Pizzi, Silvia ^a   Bottarelli, Lorena ^a   Mormandi, Francesca ^a   Antonetti, Tommaso ^a   Luong, Tu Vinh ^a   Rindi, Guido ^a  

^a UNIVERSITY OF PARMA   (Italy)

Author keywords

Foregut endocrine tumors; Ki 67; Midgut endocrine tumors; Poorly differentiated endocrine carcinoma; Prognosis; Well differentiated endocrine carcinoma; WHO classification

Indexed keywords

CHOLECYSTOKININ; CHORIONIC GONADOTROPIN ALPHA SUBUNIT; GASTRIC INHIBITORY POLYPEPTIDE; GASTRIN; GHRELIN; GLUCAGON; HISTAMINE; INSULIN; KI 67 ANTIGEN; MOTILIN; NEUROTENSIN; PANCREAS POLYPEPTIDE; PEPTIDE YY; SECRETIN; SEROTONIN; SOMATOSTATIN; TRANSCRIPTION FACTOR GLI1;

CANCER GROWTH; CANCER INFILTRATION; CANCER LOCALIZATION; CHROMOSOME 1; CHROMOSOME 16; CHROMOSOME 17P; CHROMOSOME 18Q; CHROMOSOME 3P; CHROMOSOME 4; CHROMOSOME 4P; CHROMOSOME 6; CHROMOSOME 6Q; CLINICAL FEATURE; CONFERENCE PAPER; DIAGNOSTIC APPROACH ROUTE; DIFFERENTIAL DIAGNOSIS; DISEASE MARKER; ENDOCRINE TUMOR; GASTROINTESTINAL TUMOR; GENE LOSS; GENE MUTATION; HISTOPATHOLOGY; HUMAN; METASTASIS POTENTIAL; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; TISSUE SECTION; TUMOR CLASSIFICATION; WORLD HEALTH ORGANIZATION; X CHROMOSOME; Y CHROMOSOME;

DIAGNOSIS, DIFFERENTIAL; ENDOCRINE GLAND NEOPLASMS; GASTROINTESTINAL NEOPLASMS; HUMANS; KI-67 ANTIGEN; MITOTIC INDEX; NEOPLASM INVASIVENESS; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL; WORLD HEALTH ORGANIZATION;

EID: 33845701031     PISSN: 10463976     EISSN: None     Source Type: Journal    
DOI: 10.1385/EP:17:2:119     Document Type: Conference Paper

References (51)

1. Rindi G, Leiter AB, Kopin AS, Bordi C, Solcia E. The "normal" endocrine cell of the gut: changing concepts and new evidences. Ann N Y Acad Sci 1014:1-12, 2004.
2. Capella C, Heitz PU, Höfler H, Solcia E, Klöppel G. Revised classification of neuroendocrine tumours of the lung, pancreas and gut. Virchows Arch 425:547-560, 1995.
3. Solcia E, Klöppel G, Sobin LH. Histological typing of endocrine tumours. 2nd ed. Berlin: Springer, 2000.
4. Rossi G, Valli R, Bertolini F, et al. Does mesoappendix infiltration predict a worse prognosis in incidental neuroendocrine tumors of the appendix? A clinicopathologic and immunohistochemical study of 15 cases. Am J Clin Pathol 120:706-711, 2003.
5. Plöckinger U, Rindi G, Arnold R, et al. Guidelines for the diagnosis and treatment of neuroendocrine gastrointestinal tumours - a consensus statement on behalf of the European Neuroendocrine Tumour Society (ENETS). Neuroendocrinology 80:394-424, 2004.
6. Wiedemann B, Jensen RT, Mignon M, et al. Preoperative diagnosis and surgical management of neuroendocrine gastroenteropancreatic tumors: General recommendations by a consensus workshop. World J Surg 22:309-318, 1998.
7. Öberg K. State of the art and future prospects in the management of neuroendocrine tumors. Quart J Nucl Med 44:3-12, 2000.
8. Reubi JC, Kappeler A, Waser B, Laissue J, Hipkin RW, Schonbrunn A. Immunohistochemical localization of somatostatin receptor sst2A in human tumors. Am J Pathol 153:233-245, 1998.
9. Soga J, Tazawa K. Pathologic analysis of carcinoids. Histologic reevaluation of 62 cases. Cancer 28:990-998, 1971.
10. Rindi G, Villanacci V, Ubiali A, Scarpa A. Endocrine tumors of the digestive tract and pancreas: histogenesis, diagnosis and molecular basis. Expert Rev Mol Diagn 1:323-333, 2001.
11. Canavese G, Azzoni C, Pizzi S, et al. p27: A potential main inhibitor of cell proliferation in digestive endocrine tumors but not a marker of benign behavior. Hum Pathol 32:1094-1101, 2001.
12. La Rosa S, Sessa F, Capella C, et al. Prognostic criteria in nonfunctioning pancreatic endocrine tumours. Virchows Arch 429:323-333, 1996.
13. Pizzi S, Azzoni C, Bassi D, Bottarelli L, Milione M, Bordi C. Genetic alterations in poorly differentiated endocrine carcinomas of the gastrointestinal tract. Cancer 98:1273-1282, 2003.
14. Furlan D, Cerutti R, Uccella S, et al. Different molecular profiles characterize well-differentiated endocrine tumors and poorly differentiated endocrine carcinomas of the gastroenteropancreatic tract. Clin Canc Res 10:947-957, 2004.
15. Furlan D, Bernasconi B, Uccella S, Cerutti R, Carnevali I, Capella C. Allelotypes and fluorescence in situ hybridization profiles of poorly differentiated endocrine carcinomas of different sites. Clin Canc Res 11:1765-1775, 2005.
16. Bordi C, D'Adda T, Azzoni C, Canavese G, Brandi ML. Gastrointestinal endocrine tumors: recent developments. Endocr Pathol 9:99-115, 1998.
17. Pelosi G, Bresaola E, Bogina G, et al. Endocrine tumors of the pancreas: Ki-67 immunoreactivity on paraffin sections is an independent predictor for malignancy: a comparative study with proliferating-cell nuclear antigen and progesterone receptor protein immunostaining, mitotic index, and other clinicopathologic variables. Hum Pathol 27:1124-1134, 1996.
18. Hochwald SN, Zee S, Conlon KC, et al. Prognostic factors in pancreatic endocrine neoplasms: an analysis of 136 cases with a proposal for low-grade and intermediate-grade groups. J Clin Oncol 20:2633-2642, 2002.
19. Nakasu S, Li DH, Okabe H, Nakajima M, Matsuda M. Significance of MIB-1 staining indices in meningiomas. Comparison of two counting methods. Am J Surg Pathol 25:472-478, 2001.
20. Rindi G, Azzoni C, La Rosa S, et al. ECL cell tumor and poorly differentiated endocrine carcinoma of the stomach: prognostic evaluation by pathological analysis. Gastroenterology 116:532-542, 1999.
21. Deshpande V, Fernandez del Castillo C, Muzikansky A, et al. Cytokeratin 19 is a powerful predictor of survival in pancreatic endocrine tumors. Am J Surg Pathol 28:1145-1153, 2004.
22. Chaudhry A, Öberg K, Wilander E. A study of biological behavior based on the expression of a proliferating antigen in neuroendocrine tumors of the digestive system. Tumor Biol 13:27-35, 1992.
23. Heitz PU, Kasper M, Klöppel G, Polak JM, Vaitukaitis JL. Glycoprotein-hormone alpha-chain production by pancreatic endocrine tumors: a specific marker for malignancy. Immunocytochemical analysis of tumors of 155 patients. Cancer 51:277-282, 1983.
24. Bordi C, Pilato FP, D'Adda T. Comparative study of seven neuroendocrine markers in pancreatic endocrine tumours. Virchows Arch A 413:387-398, 1988.
25. Graeme-Cook F, Nardi G, Compton C. Immunocytochemical staining for human chorionic gonadotropin subunits does not predict malignancy in insulinomas. Am J Clin Pathol 93:273-276, 1990.
26. Donow C, Baisch H, Heitz PU, Klöppel G. Nuclear DNA content in 27 pancreatic endocrine tumours. Correlation with malignancy, survival and expression of glycoprotein hormone alpha chain. Virchows Arch (Path Anat) 419:463-468, 1991.
27. Bordi C, Pilato FP, Bertelé A, D'Adda T, Missale G. Expression of glycoprotein hormone alpha-subunit by endocrine cells of the oxyntic mucosa is associated with hypergastrinemia. Hum Pathol 19:580-585, 1988.
28. Bordi C, D'Adda T, Azzoni C, Pilato FP, Caruana P. Hypergastrinemia and gastric enterochromaffin-like cells. Am J Surg Pathol 19 (suppl 1):S8-S19, 1995.
29. Bordi C, D'Adda T, Azzoni C, Ferraro G. Pathogenesis of ECL cell tumors in humans. Yale J Biol Med 71:273-284, 1998.
30. Fukayama M, Hayashi Y, Shiozawa Y, Okabe S, Koike M. Human chorionic gonadotropin alpha-subunit in rectal carcinoids. Its mode of presence and the change of granule morphology. Am J Pathol 135:1065-1072, 1989.
31. Carlinfante G, Lampugnani R, Azzoni C, Aprile MR, Brandi ML, Bordi C. Expression of the α- and β-subunits of human chorionic gonadotropin by subsets of parathyroid cells in states of hyperparathyroidism. J Pathol 185:389-393, 1998.
32. Goto A, Niki T, Terado Y, Fukushima J, Fukayama M. Prevalence of CD99 protein expression in pancreatic endocrine tumours (PETs). Histopathology 45:384-392, 2004.
33. Rigaud G, Missiaglia E, Moore PS, et al. High resolution allelotype of nonfunctional pancreatic endocrine tumors: identification of two molecular subgroups with clinical implications. Cancer Res 61:285-292, 2001.
34. Pizzi S, D'Adda T, Azzoni C, et al. Malignancy-associated allelic losses on X chromosome in foregut but not in midgut endocrine tumours. J Pathol 196:401-407, 2002.
35. Pizzi S, Azzoni C, Bottarelli L, et al. RASSF1A promoter methylation and 3p21.3 LOH label foregut, but not midgut and hindgut, malignant endocrine tumours. J Pathol 206:409-416, 2005.
36. Leotlela PD, Jauch A, Holtgreve Grez H, Thakker RV. Genetics of neuroendocrine and carcinoid tumours. Endoc Relat Cancer 10:437-450, 2003.
37. Bordi C, D'Adda T, Pizzi S, Crafa P, Rindi G. The assessment of malignancy in endocrine tumours of the gastrointestinal tract. Curr Diagn Pathol 8:421-429, 2002.
38. Ebrahimi SA, Wang EH, Wu A, Schreck RR, Passaro E, Sawicki MP. Deletion of chromosome 1 predicts prognosis in pancreatic endocrine tumors. Cancer Res 59:311-315, 1999.
39. Speel EJM, Richter J, Moch H, et al. Genetic differences in endocrine pancreatic tumor subtypes detected by comparative genomic hybridization. Am J Pathol 155:1787-1794, 1999.
40. Chung DC, Smith AP, Louis DN, Graeme-Cook F, Warshaw AL, Arnold A. A novel pancreatic endocrine tumor suppressor gene locus on chromosome 3p with clinical prognostic implications. J Clin Invest 100:404-410, 1997.
41. Hessman O, Lindberg D, Einarsson A, et al. Genetic alterations on 3p, 11q13, and 18q in nonfamilial and MEN 1-associated pancreatic endocrine tumors. Gene Chromosome Canc 26:258-264, 1999.
42. Barghorn A, Komminoth P, Bachmann D, et al. Deletion at 3p25.3-p23 is frequently encountered in endocrine pancreatic tumours and is associated with metastatic progression. J Pathol 194:451-458, 2001.
43. Zhao JM, Moch H, Scheidweiler AF, et al. Genomic imbalances in the progression of endocrine pancreatic tumors. Gene Chromosome Canc 32:364-372, 2001.
44. Kytola S, Hoog A, Nord B, et al. Comparative genomic hybridization identifies loss of 18q22-qter as an early and specific event in tumorigenesis of midgut carcinoids. Am J Pathol 158:1803-1808, 2001.
45. Barghorn A, Speel EJM, Farspour B, et al. Putative tumor suppressor loci at 6q22 and 6q23-q24 are involved in the malignant progression of sporadic endocrine pancreatic tumors. Am J Pathol 158:1903-1911, 2001.
46. Beghelli S, Pelosi G, Zamboni G, et al. Pancreatic endocrine tumours: evidence for a tumour suppressor pathogenesis and for a tumour suppressor gene on chromosome 17p. J Pathol 186:41-50, 1998.
47. Rindi G, Alberizzi P, Candusso M, La Rosa S, Capella C, Solcia E. Loss of heterozygosity for chromosome 17p, P53 gene, and chromosome 18q, DCC gene, in aggressive endocrine tumors of the stomach. Gastroenterology 116:G2156 (Abstract), 1999.
48. Vortmeyer AO, Lubensky IA, Merino MJ, et al. Concordance of genetic alterations in poorly differentiated colorectal neuroendocrine carcinomas and associated adenocarcinomas. J Natl Cancer Inst 89:1448-1453, 1997.
49. D'Adda T, Candidus S, Bordi C, Hoffler H. Gastric neuroendocrine neoplasms: tumor clonality and malignancy associated large X-chromosomal deletions. J Pathol 189:394-401, 1999.
50. Missiaglia E, Moore PS, Williamson J, et al. Sex chromosome anomalies in pancreatic endocrine tumors. Int J Cancer 98:532-538, 2002.
51. Brandi ML, Bordi C, Falchetti A, Tonelli F, Marx SJ. Multiple endocrine neoplasia type 1. In: Brandi ML, Bordi C, Falchetti A, Tonelli F, Marx SJ, eds. Principles of Bone Biology. San Diego: Academic Press, 1996; 783-797.